Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2017-07-06Clinical Trial Update: Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation [Phase 1, Phase 2]
A completed Phase 1/2 sequential trial of reduced-intensity conditioning allogeneic transplantation in patients with hematologic malignancie…
-
CLINICAL_TRIALS trial_result · 2017-07-06Clinical Trial Update: Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma [Phase 3]
This entry describes a Phase 3 clinical trial evaluating lenalidomide and dexamethasone with or without bortezomib as initial treatment for …
-
CLINICAL_TRIALS withdrawal · 2017-07-05Clinical Trial Update: GO-203-2C + Bortezomib For Relapsed Or Refractory MM [Phase 1]
A Phase 1 trial of GO-203-2C plus bortezomib for relapsed or refractory multiple myeloma has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2017-06-28Clinical Trial Update: Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant [Phase 2]
This Phase 2 trial evaluated sirolimus, tacrolimus, and antithymocyte globulin to prevent graft-versus-host disease in patients with hematol…
-
CLINICAL_TRIALS trial_result · 2017-06-28Clinical Trial Update: First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade [Phase 2]
A Phase 2 clinical trial investigates autologous stem cell transplantation guided by minimal residual disease markers in newly diagnosed mul…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2017-06-27FDA Approved: POMALYST — Supplemental Application (Celgene Corporation)
The FDA approved a supplemental application for POMALYST (pomalidomide) submitted by Celgene Corporation.
-
CLINICAL_TRIALS trial_result · 2017-06-27Clinical Trial Update: Randomized Trial of Cryotherapy Duration Prior to High Dose Melphalan in Myeloma Patients [NA]
Completed randomized trial evaluating the duration of cryotherapy before high-dose melphalan in myeloma patients.
-
CLINICAL_TRIALS research · 2017-06-27Clinical Trial Update: Collection of Patient-Reported Symptoms and Performance Status Via the Internet [NA]
This is a completed clinical trial update describing online collection of patient-reported symptoms and performance status across multiple c…
-
CLINICAL_TRIALS trial_result · 2017-06-26Clinical Trial Update: Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant [Phase 2]
Phase 2 trial assessing thalidomide, dexamethasone, and clarithromycin in patients with multiple myeloma previously treated with transplant;…
-
CLINICAL_TRIALS trial_result · 2017-06-23Clinical Trial Update: Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma [Phase 2]
Phase II study evaluating a combination of thalidomide, clarithromycin, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma …
-
CLINICAL_TRIALS trial_result · 2017-06-21Clinical Trial Update: Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib [Phase 2]
Phase 2 study evaluating high-dose carfilzomib in multiple myeloma patients who progressed on standard-dose carfilzomib; the trial is comple…
-
FDA approval · 2017-06-16FDA Approved: DARZALEX — Supplemental Application (Janssen Biotech, Inc.)
The FDA approved a supplemental application for DARZALEX (daratumumab) submitted by Janssen Biotech, Inc. to modify/expand the approved use.
-
CLINICAL_TRIALS trial_result · 2017-06-14Clinical Trial Update: Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease [Phase 2]
Phase 2 trial update describing donor umbilical cord blood transplantation for advanced hematologic cancers, including leukemia, lymphoma, m…
-
CLINICAL_TRIALS trial_result · 2017-06-14Clinical Trial Update: Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning Chemotherapy for Autologous SCT [Phase 2]
Phase 2 trial evaluating strategies to manage diarrhea in patients with multiple myeloma undergoing conditioning chemotherapy for autologous…
-
CLINICAL_TRIALS trial_result · 2017-06-14Clinical Trial Update: Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma [Phase 2]
Phase II study evaluating fenofibrate therapy in patients with smoldering or symptomatic multiple myeloma has been terminated; results were …
-
CLINICAL_TRIALS trial_result · 2017-06-14Clinical Trial Update: Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies [NA]
Clinical trial update for fludarabine-based conditioning prior to allogeneic transplantation in advanced hematologic malignancies; study com…
-
CLINICAL_TRIALS trial_result · 2017-06-14Clinical Trial Update: Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment [Phase 2]
A Phase 2 trial of tandem autologous stem cell transplantation in multiple myeloma patients with less than 12 months of prior therapy was te…
-
FDA approval · 2017-06-09FDA Approved: VELCADE — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for Velcade (bortezomib) filed by Takeda Pharmaceuticals America, Inc., expanding or modifying i…
-
CLINICAL_TRIALS trial_result · 2017-06-08Clinical Trial Update: Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma [Phase 2]
Phase II trial evaluating a combination of dexamethasone, thalidomide, and lenalidomide in relapsed or refractory multiple myeloma; the stud…
-
CLINICAL_TRIALS trial_result · 2017-06-06Clinical Trial Update: Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies [Phase 1, Phase 2]
Phase 1/2 study evaluating plerixafor (AMD3100) as a stem cell mobilizer for transplantation from a sibling donor in various hematologic mal…
-
CLINICAL_TRIALS withdrawal · 2017-06-05Clinical Trial Update: A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment [Phase 1]
This document notes the withdrawal of a Phase 1 clinical trial evaluating a combination of venetoclax and ABBV-838 with dexamethasone in par…
-
CLINICAL_TRIALS trial_result · 2017-05-31Clinical Trial Update: Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma [Phase 2]
Phase 2 trial of Velcade (bortezomib) plus cyclophosphamide in newly diagnosed multiple myeloma was terminated; results were posted in 2017.
-
CLINICAL_TRIALS withdrawal · 2017-05-31Clinical Trial Update: Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects
The clinical trial examining early myocardial infiltration due to amyloid and light chain deposition in multiple myeloma patients has been t…
-
CLINICAL_TRIALS trial_result · 2017-05-30Clinical Trial Update: Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease [Phase 2]
Phase 2 trial evaluating reduced-intensity conditioning with busulfan and fludarabine, with or without antithymocyte globulin, followed by d…
-
CLINICAL_TRIALS trial_result · 2017-05-30Clinical Trial Update: T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases [Phase 2]
Phase 2 study evaluating T-cell depletion and donor hematopoietic stem cell transplantation with T-cell infusions in patients with various h…